GSK
GSK shares results from phase 3 trial for Blenrep for treatment of multiple myeloma
March 7, 2024Research and Development Blenrep, GSK, Oncology, clinical trial, multiple myeloma
GSK has announced positive results from an interim analysis of the DREAMM-8 phase 3 head-to-head trial which assesses Blenrep (belantamab …
GSK’s Jemperli recommended by NICE for endometrial cancer treatment
March 5, 2024Medical Communications GSK, Jemperli, NICE, Oncology, endometrial cancer
GSK has announced that the National Institute for Health and Care Excellence (NICE) has recommended the use of Jemperli (dostarlimab) …
GSK shares positive results from phase 3 trial for gonorrhoea treatment
February 27, 2024Research and Development GSK, Infections and infestations, antibiotic, clinical trial, gonorrhoea
GSK has announced positive headline results from its phase 3 EAGLE-1 trial for gepotidacin, its potential first-in-class oral antibiotic with …
GSK gains FDA Fast Track designation for chronic hepatitis B treatment
February 12, 2024Medical Communications FDA, GSK, Hepatology, fast track designation, hepatitis B
GSK has announced that the US Food and Drug Administration (FDA) has granted Fast Track designation for bepirovirsen, an investigational …
MHRA approves GSK’s Omjjara in Great Britain for splenomegaly treatment
January 31, 2024Medical Communications GSK, MHRA, Omjjara, Oncology, myelofibrosis, splenomegaly
GSK has announced that the Medicines and Healthcare products Regulatory Agency (MHRA) has granted Marketing Authorisation to Omjjara (momelotinib) in …
GSK to acquire Aiolos Bio for $1bn
January 9, 2024Business Services Aiolos Bio, GSK, Pharmacy, acquisition
GSK and Aiolos Bio have announced that they have entered into an agreement for GSK to acquire Aiolos for an …
GSK shares results for Jemperli plus Zejula combination of endometrial cancer treatment
December 18, 2023Research and Development GSK, Jemperli, Oncology, Zejula, endometrial cancer
GSK has announced positive results from a planned analysis of the second part of the RUBY/ENGOT-EN6/GOG3031/NSGO phase 3 trial which …
GSK’s Jemperli approved in EU as treatment for endometrial cancer
December 11, 2023Medical Communications EU, GSK, Jemperli, Oncology, endometrial cancer
GSK has announced that the European Commission (EC) has granted marketing authorisation to Jemperli (dostarlimab) in combination with carboplatin-paclitaxel chemotherapy, …
GSK shares data from global shingles survey
December 1, 2023Medical Communications GSK, Infections and infestations, data, shingles
GSK has announced data from its new global survey about shingles. The data suggests that there are some significant gaps …
GSK shares results from phase 3 trial for Blenrep as multiple myeloma treatment
November 27, 2023Medical Communications Blenrep, GSK, Oncology, clinical trial, multiple myeloma
GSK has announced positive results from a planned interim efficacy analysis of the phase 3 DREAMM-7 head-to-head trial which assessed …
GSK’s low carbon inhaler, Ventolin, progresses to phase 3 trialsÂ
November 21, 2023Medical Communications Asthma & COPD, GSK, Ventolin, asthma, carbon-neutral
GSK has announced that in 2024 it intends to start phase 3 trials of a low carbon version of its …
GSK gains positive CHMP opinion for momelotinib for myelofibrosis treatment
November 13, 2023Medical Communications CHMP, GSK, Haematology, anaemia, momelotinib, myelofibrosis
GSK has announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has …
GSK enters agreement for license for JNJ-3089 for development of bepirovirsen
November 2, 2023Medical Communications Arrowhead Pharmaceuticals, GSK, Infections and infestations, Janssen, hepatitis B
GSK and Arrowhead Pharmaceuticals have announced that they have come to an agreement with Janssen Pharmaceuticals, a Johnson & Johnson …
GSK shares results from phase 3 RUBY trial of Jemperli for endometrial cancer treatment
October 30, 2023Medical Communications Cancer, GSK, Jemperli, Oncology, endometrial cancer
GSK has announced positive headline results from an analysis of part 1 of the RUBY/ENGOT-EN6/GOG3031/NSGO phase 3 trial which assessed …
GSK shares new data for RSV vaccine Arexvy
October 25, 2023Research and Development Arexvy, GSK, Immunology, RSV, Vaccine
GSK announced positive results from its phase 3 trial which assessed the immune response and safety of Arexvy, its respiratory …
Latest content
ESTEVE CDMO adds $17.5m to Illinois expansion
Brenntag and dsm-firmenich expand biopharma vitamin partnership
